-
11599-50A potent, highly selective inhibitor of MEK1 and MEK2 (IC50 = 14-99 and 530 nM, respectively) weakly inhibits EGFR (IC50 = 7.0 µM) and has no effect on a large panel of other kinases suppresses growth and induces apoptosis and
-
19282-1An inhibitor of PDKs, resulting in an increase in PDH activity (EC<sub>50</sub> = 5.2 nM for PDK2) less potently inhibits PDK1 and PDK3 (IC<sub>50</sub>s = 87 and 600 nM, respectively).
-
19282-10An inhibitor of PDKs, resulting in an increase in PDH activity (EC<sub>50</sub> = 5.2 nM for PDK2) less potently inhibits PDK1 and PDK3 (IC<sub>50</sub>s = 87 and 600 nM, respectively).
-
19282-25An inhibitor of PDKs, resulting in an increase in PDH activity (EC<sub>50</sub> = 5.2 nM for PDK2) less potently inhibits PDK1 and PDK3 (IC<sub>50</sub>s = 87 and 600 nM, respectively).
-
19282-5An inhibitor of PDKs, resulting in an increase in PDH activity (EC<sub>50</sub> = 5.2 nM for PDK2) less potently inhibits PDK1 and PDK3 (IC<sub>50</sub>s = 87 and 600 nM, respectively).
-
11491-1Selectively inhibits checkpoint kinases Chk1 and Chk2 (IC50s = 5 nM) abrogates DNA damage-induced S and G2 checkpoints (EC50 = 10 nM) and potentiates the efficacy of gemcitabine and topotecan by modulating downstream checkpoint pathway proteins.
-
11491-10Selectively inhibits checkpoint kinases Chk1 and Chk2 (IC50s = 5 nM) abrogates DNA damage-induced S and G2 checkpoints (EC50 = 10 nM) and potentiates the efficacy of gemcitabine and topotecan by modulating downstream checkpoint pathway proteins.
-
11491-25Selectively inhibits checkpoint kinases Chk1 and Chk2 (IC50s = 5 nM) abrogates DNA damage-induced S and G2 checkpoints (EC50 = 10 nM) and potentiates the efficacy of gemcitabine and topotecan by modulating downstream checkpoint pathway proteins.
-
11491-5Selectively inhibits checkpoint kinases Chk1 and Chk2 (IC50s = 5 nM) abrogates DNA damage-induced S and G2 checkpoints (EC50 = 10 nM) and potentiates the efficacy of gemcitabine and topotecan by modulating downstream checkpoint pathway proteins.
-
16978-1A potent, selective ATP-competitive inhibitor of mTOR (IC<sub>50</sub> = 0.8 nM) inhibits proliferation of A549 (IC<sub>50</sub> = 53 nM) and H838 cells (IC<sub>50</sub> = 20 nM) as well as several human tumor xenografts (>65% at 20 mg/kg).
-
16978-10A potent, selective ATP-competitive inhibitor of mTOR (IC<sub>50</sub> = 0.8 nM) inhibits proliferation of A549 (IC<sub>50</sub> = 53 nM) and H838 cells (IC<sub>50</sub> = 20 nM) as well as several human tumor xenografts (>65% at 20 mg/kg).
-
16978-5A potent, selective ATP-competitive inhibitor of mTOR (IC<sub>50</sub> = 0.8 nM) inhibits proliferation of A549 (IC<sub>50</sub> = 53 nM) and H838 cells (IC<sub>50</sub> = 20 nM) as well as several human tumor xenografts (>65% at 20 mg/kg).